ImmuCell Net Income vs. Shares Owned By Institutions
| ICCC Stock | USD 3.69 0.03 0.82% |
Net Loss | First Reported 1989-06-30 | Previous Quarter -1.5 M | Current Value -701.7 M | Quarterly Volatility 62.3 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.24 | 0.2516 |
|
|
For ImmuCell profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ImmuCell to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ImmuCell utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ImmuCell's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ImmuCell over time as well as its relative position and ranking within its peers.
ImmuCell |
ImmuCell's Revenue Breakdown by Earning Segment
Check out Risk vs Return Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share 2.991 | Quarterly Revenue Growth 0.549 | Return On Assets (0.05) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ImmuCell Shares Owned By Institutions vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ImmuCell's current stock value. Our valuation model uses many indicators to compare ImmuCell value to that of its competitors to determine the firm's financial worth. ImmuCell is rated second overall in net income category among its peers. It is rated below average in shares owned by institutions category among its peers . At present, ImmuCell's Net Loss is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmuCell's earnings, one of the primary drivers of an investment's value.ImmuCell Shares Owned By Institutions vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
ImmuCell |
| = | (5.77 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
ImmuCell |
| = | 14.51 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
ImmuCell Shares Owned By Institutions Comparison
ImmuCell is currently under evaluation in shares owned by institutions category among its peers.
ImmuCell Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ImmuCell, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ImmuCell will eventually generate negative long term returns. The profitability progress is the general direction of ImmuCell's change in net profit over the period of time. It can combine multiple indicators of ImmuCell, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -5.7 M | -5.5 M | |
| Net Loss | -5.8 M | -5.5 M | |
| Income Tax Expense | 4.6 K | 4.4 K | |
| Income Before Tax | -5.8 M | -5.5 M | |
| Total Other Income Expense Net | -21.9 K | -20.8 K | |
| Net Loss | -2.2 B | -2.1 B | |
| Net Loss | -6.3 M | -6 M | |
| Non Operating Income Net Other | 313.3 K | 329 K | |
| Interest Income | 143.8 K | 74.4 K | |
| Net Interest Income | -273 K | -286.6 K | |
| Change To Netincome | 330.5 M | 347 M | |
| Net Loss | (0.75) | (0.71) | |
| Income Quality | 0.81 | 1.11 | |
| Net Income Per E B T | 1.00 | 0.96 |
ImmuCell Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ImmuCell. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ImmuCell position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ImmuCell's important profitability drivers and their relationship over time.
Use ImmuCell in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmuCell position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmuCell will appreciate offsetting losses from the drop in the long position's value.ImmuCell Pair Trading
ImmuCell Pair Trading Analysis
The ability to find closely correlated positions to ImmuCell could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ImmuCell when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ImmuCell - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ImmuCell to buy it.
The correlation of ImmuCell is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ImmuCell moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ImmuCell moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ImmuCell can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ImmuCell position
In addition to having ImmuCell in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Artificial Intelligence Thematic Idea Now
Artificial Intelligence
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
To fully project ImmuCell's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ImmuCell at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ImmuCell's income statement, its balance sheet, and the statement of cash flows.